Related Experiment Video

Updated: Jul 4, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional

Lionel Apetoh1, Antoine Tesniere, François Ghiringhelli

  • 1Institut National de la Sante et de la Recherche Medicale, U805, Villejuif, France.

Cancer Research
|June 4, 2008
PubMed

Insights

Chemotherapy and radiotherapy trigger tumor cell death, initiating an immune response that aids treatment success. This pathway involves high mobility group box 1 protein (HMGB1) and Toll-like receptor 4 (TLR4), crucial for anti-tumor T-cell activity.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Anticancer treatment efficacy is traditionally measured by direct tumor cell killing.
  • Emerging evidence suggests that treatment-induced tumor cell death can activate immune responses, enhancing therapeutic outcomes.

Purpose of the Study:

  • To investigate the role of tumor cell death in initiating an immunoadjuvant pathway.
  • To elucidate the specific molecular interactions involved in this immune activation process.

Main Methods:

  • Analysis of tumor cell death pathways induced by chemotherapy and radiotherapy.
  • Investigating the interaction between high mobility group box 1 protein (HMGB1) and Toll-like receptor 4 (TLR4) on dendritic cells.
  • Assessing cytotoxic T-cell responses and tumor antigen crosspresentation.
  • Correlating Toll-like receptor 4 (TLR4) polymorphisms with patient relapse rates in breast cancer.

Main Results:

  • Tumor cell death releases high mobility group box 1 protein (HMGB1).
  • HMGB1 interacts with Toll-like receptor 4 (TLR4) on dendritic cells, facilitating tumor antigen crosspresentation.
  • This interaction promotes tumor-specific cytotoxic T-cell responses.
  • Breast cancer patients with a loss-of-function TLR4 polymorphism (Asp299Gly) experienced earlier relapse after anthracycline chemotherapy.

Conclusions:

  • Conventional cancer treatments, through HMGB1 and TLR4-dependent pathways, can stimulate immune responses that contribute to durable therapeutic success.
  • Targeting or understanding these immune pathways may offer new strategies for improving cancer treatment efficacy.

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle12:19

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle

Published on: June 7, 2024

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...